[
  {
    "ts": null,
    "headline": "Why Shares of Novo Nordisk Stock Sank (Again) This Week",
    "summary": "The weight-loss drug innovator is falling behind in the industry and facing major pricing pressures.",
    "url": "https://finnhub.io/api/news?id=5ec56e8ec17a1f6ae900604811fa737a1ea1c85cd7272743283b4834c63e53b9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772139567,
      "headline": "Why Shares of Novo Nordisk Stock Sank (Again) This Week",
      "id": 139239785,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The weight-loss drug innovator is falling behind in the industry and facing major pricing pressures.",
      "url": "https://finnhub.io/api/news?id=5ec56e8ec17a1f6ae900604811fa737a1ea1c85cd7272743283b4834c63e53b9"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer Highlights Elanco’s “Comeback Story”",
    "summary": "Elanco Animal Health Incorporated (NYSE:ELAN) is one of the stocks Jim Cramer commented on. Cramer highlighted the stock’s terrific performance over the last 12 months, as he commented: I love a good comeback story. Right now, there’s a great one playing out in Elanco Animal Health. That’s a veterinary medicine company spun off by Eli […]",
    "url": "https://finnhub.io/api/news?id=d3c7279835d370933ca0a81ebdc47314b752bfa566eab4015c9a9060b2378be7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772138559,
      "headline": "Jim Cramer Highlights Elanco’s “Comeback Story”",
      "id": 139239786,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Elanco Animal Health Incorporated (NYSE:ELAN) is one of the stocks Jim Cramer commented on. Cramer highlighted the stock’s terrific performance over the last 12 months, as he commented: I love a good comeback story. Right now, there’s a great one playing out in Elanco Animal Health. That’s a veterinary medicine company spun off by Eli […]",
      "url": "https://finnhub.io/api/news?id=d3c7279835d370933ca0a81ebdc47314b752bfa566eab4015c9a9060b2378be7"
    }
  },
  {
    "ts": null,
    "headline": "Biogen Faces Uncertain Outlook for Alzheimer's Drug But Pipeline Supports Growth, RBC Says",
    "summary": "Biogen's (BIIB) new Alzheimer's drug, BIIB080, has mid-year results coming up and its success is unc",
    "url": "https://finnhub.io/api/news?id=989b789e0cd5bf0671707091c075df26571131b03e44c5cce957481506efa455",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772126232,
      "headline": "Biogen Faces Uncertain Outlook for Alzheimer's Drug But Pipeline Supports Growth, RBC Says",
      "id": 139237020,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Biogen's (BIIB) new Alzheimer's drug, BIIB080, has mid-year results coming up and its success is unc",
      "url": "https://finnhub.io/api/news?id=989b789e0cd5bf0671707091c075df26571131b03e44c5cce957481506efa455"
    }
  },
  {
    "ts": null,
    "headline": "ETFs to Buy as NVIDIA Shares Gain Following Q4 Earnings Beat",
    "summary": "NVDA jumps after crushing Q4 earnings and strong guidance, lifting ETF plays like SMH tied to the AI chip leader.",
    "url": "https://finnhub.io/api/news?id=779aab3c851a49d6851898175826a9bf3a1453559fcb138ede874ece934e567b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772124720,
      "headline": "ETFs to Buy as NVIDIA Shares Gain Following Q4 Earnings Beat",
      "id": 139238421,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "NVDA jumps after crushing Q4 earnings and strong guidance, lifting ETF plays like SMH tied to the AI chip leader.",
      "url": "https://finnhub.io/api/news?id=779aab3c851a49d6851898175826a9bf3a1453559fcb138ede874ece934e567b"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Says Orforglipron Outperforms Oral Semaglutide in Phase 3 Trial",
    "summary": "Eli Lilly (LLY) said Thursday its experimental oral GLP-1 receptor agonist orforglipron outperformed",
    "url": "https://finnhub.io/api/news?id=a6871b76dfddb4cca5c5d445f40fa0f02f07ad72d90b9ea77b9ddda3412c53cb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772120285,
      "headline": "Eli Lilly Says Orforglipron Outperforms Oral Semaglutide in Phase 3 Trial",
      "id": 139235359,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) said Thursday its experimental oral GLP-1 receptor agonist orforglipron outperformed",
      "url": "https://finnhub.io/api/news?id=a6871b76dfddb4cca5c5d445f40fa0f02f07ad72d90b9ea77b9ddda3412c53cb"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer Recommends Eli Lilly over Novo Nordisk",
    "summary": "Novo Nordisk A/S (NYSE:NVO) is one of the stocks Jim Cramer commented on. Answering a caller’s question about the stock during the lightning round, Cramer said: Oh no, you don’t want to be in Novo Nordisk. You want to be in Eli Lilly. Novo Nordisk is really good at cutting prices. Eli Lilly’s great at […]",
    "url": "https://finnhub.io/api/news?id=fd7e01205d98446487b80e59007021f9b7a04aef33d813cf19c69f9bb5ecfc3d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772117802,
      "headline": "Jim Cramer Recommends Eli Lilly over Novo Nordisk",
      "id": 139235360,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk A/S (NYSE:NVO) is one of the stocks Jim Cramer commented on. Answering a caller’s question about the stock during the lightning round, Cramer said: Oh no, you don’t want to be in Novo Nordisk. You want to be in Eli Lilly. Novo Nordisk is really good at cutting prices. Eli Lilly’s great at […]",
      "url": "https://finnhub.io/api/news?id=fd7e01205d98446487b80e59007021f9b7a04aef33d813cf19c69f9bb5ecfc3d"
    }
  },
  {
    "ts": null,
    "headline": "Why Is CRISPR Therapeutics Stock Surging Thursday?",
    "summary": "CRSP shares jump on earnings report, strong pipeline for gene therapy. Revenue grows with increased patient treatment and analyst confidence.",
    "url": "https://finnhub.io/api/news?id=26f931442be9b6328f1407d639df42ff827d5cb462764189066f69661c22af2b",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772117146,
      "headline": "Why Is CRISPR Therapeutics Stock Surging Thursday?",
      "id": 139246942,
      "image": "https://cdn.benzinga.com/files/images/story/2026/02/26/Crispr-Therapeutics.jpeg?width=2048&height=1536",
      "related": "LLY",
      "source": "Benzinga",
      "summary": "CRSP shares jump on earnings report, strong pipeline for gene therapy. Revenue grows with increased patient treatment and analyst confidence.",
      "url": "https://finnhub.io/api/news?id=26f931442be9b6328f1407d639df42ff827d5cb462764189066f69661c22af2b"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly's New Oral Weight Loss Drug Outperforms Semaglutide, Eyes Potential US Approval In Q2",
    "summary": "Eli Lilly shares rise after orforglipron beats Novo&#39;s drug in Phase 3, cutting A1C by 2.2% and boosting weight loss results.",
    "url": "https://finnhub.io/api/news?id=5b6e98ab6e7fe470aba15057cef1b530d1336c8e4af915333b1a1081828f69c6",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772114394,
      "headline": "Eli Lilly's New Oral Weight Loss Drug Outperforms Semaglutide, Eyes Potential US Approval In Q2",
      "id": 139247025,
      "image": "https://cdn.benzinga.com/files/images/story/2026/02/26/Eli-Lilly.jpeg?width=2048&height=1536",
      "related": "LLY",
      "source": "Benzinga",
      "summary": "Eli Lilly shares rise after orforglipron beats Novo&#39;s drug in Phase 3, cutting A1C by 2.2% and boosting weight loss results.",
      "url": "https://finnhub.io/api/news?id=5b6e98ab6e7fe470aba15057cef1b530d1336c8e4af915333b1a1081828f69c6"
    }
  },
  {
    "ts": null,
    "headline": "10 Health Care Stocks Whale Activity In Today's Session",
    "summary": "",
    "url": "https://finnhub.io/api/news?id=cf0466e3c8cb3ff3ed9c2bfbb962deb01f43035da2b9ca0e4a6fff80fb1b0339",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772112927,
      "headline": "10 Health Care Stocks Whale Activity In Today's Session",
      "id": 139247004,
      "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_3.jpg?width=2048&height=1536",
      "related": "LLY",
      "source": "Benzinga",
      "summary": " ",
      "url": "https://finnhub.io/api/news?id=cf0466e3c8cb3ff3ed9c2bfbb962deb01f43035da2b9ca0e4a6fff80fb1b0339"
    }
  },
  {
    "ts": null,
    "headline": "OTF + Lilly Collaboration Update on Registration Response | OMA QI Scaling Initiative Gains National Response, Bringing Together Diverse Practice Types Across 39 States",
    "summary": "Denver, Colorado--(Newsfile Corp. - February 26, 2026) - The Obesity Medicine Association (OMA) is seeing strong early momentum for its Implementation into Practice Collaborative (IPC), a program designed to help clinicians strengthen obesity care through practical, evidence-based improvements in outpatient settings.The IPC is part of a multi-phase Quality Improvement (QI) initiative created specifically for OMA members. It was developed in collaboration with the Obesity Treatment Foundation...",
    "url": "https://finnhub.io/api/news?id=d07176a98f413de3e14b26cf3ec871482698f1e4265848b3e58f84f927e2120d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772110800,
      "headline": "OTF + Lilly Collaboration Update on Registration Response | OMA QI Scaling Initiative Gains National Response, Bringing Together Diverse Practice Types Across 39 States",
      "id": 139232143,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Denver, Colorado--(Newsfile Corp. - February 26, 2026) - The Obesity Medicine Association (OMA) is seeing strong early momentum for its Implementation into Practice Collaborative (IPC), a program designed to help clinicians strengthen obesity care through practical, evidence-based improvements in outpatient settings.The IPC is part of a multi-phase Quality Improvement (QI) initiative created specifically for OMA members. It was developed in collaboration with the Obesity Treatment Foundation...",
      "url": "https://finnhub.io/api/news?id=d07176a98f413de3e14b26cf3ec871482698f1e4265848b3e58f84f927e2120d"
    }
  },
  {
    "ts": null,
    "headline": "Soleno Therapeutics Announces Retirement of James Mackaness and Appointment of Jennifer Fulk as Chief Financial Officer",
    "summary": "REDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointment of Jennifer Fulk as Chief Financial Officer, succeeding James Mackaness, who announced that he will be retiring from the Company by the end of the first quarter. Mr. Mackaness will serve as a consultant to Soleno through the end of the year to ensure a smooth transit",
    "url": "https://finnhub.io/api/news?id=c06f1a3fcbf03cb189281f866b64ec94782cbefbbbbf7cd23941c86e66885442",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772110800,
      "headline": "Soleno Therapeutics Announces Retirement of James Mackaness and Appointment of Jennifer Fulk as Chief Financial Officer",
      "id": 139232142,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "REDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointment of Jennifer Fulk as Chief Financial Officer, succeeding James Mackaness, who announced that he will be retiring from the Company by the end of the first quarter. Mr. Mackaness will serve as a consultant to Soleno through the end of the year to ensure a smooth transit",
      "url": "https://finnhub.io/api/news?id=c06f1a3fcbf03cb189281f866b64ec94782cbefbbbbf7cd23941c86e66885442"
    }
  },
  {
    "ts": null,
    "headline": "Hims & Hers: The Telehealth Growth Story Younger Investors Can't Afford to Ignore",
    "summary": "How fast can Hims & Hers grow without selling GLP-1 drugs? Maybe a lot faster than you think.",
    "url": "https://finnhub.io/api/news?id=f8aa3544de0b80b655c73ffc43bd2f93d1bd5b3687ef81ae7b76e8b25da50a2c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772109420,
      "headline": "Hims & Hers: The Telehealth Growth Story Younger Investors Can't Afford to Ignore",
      "id": 139232144,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "How fast can Hims & Hers grow without selling GLP-1 drugs? Maybe a lot faster than you think.",
      "url": "https://finnhub.io/api/news?id=f8aa3544de0b80b655c73ffc43bd2f93d1bd5b3687ef81ae7b76e8b25da50a2c"
    }
  },
  {
    "ts": null,
    "headline": "Lilly’s GLP-1 pill tops Novo’s Rybelsus in head-to-head trial",
    "summary": "Orforglipron, which could be approved for obesity next quarter, proved superior at cutting blood sugar and body weight — but at the expense of higher side effect rates.",
    "url": "https://finnhub.io/api/news?id=eb4bee1ecbf86751b17d9936dc5b3d8d5b854f134b5cf868d946f6c05aacb949",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772107800,
      "headline": "Lilly’s GLP-1 pill tops Novo’s Rybelsus in head-to-head trial",
      "id": 139237021,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Orforglipron, which could be approved for obesity next quarter, proved superior at cutting blood sugar and body weight — but at the expense of higher side effect rates.",
      "url": "https://finnhub.io/api/news?id=eb4bee1ecbf86751b17d9936dc5b3d8d5b854f134b5cf868d946f6c05aacb949"
    }
  },
  {
    "ts": null,
    "headline": "Lilly's oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet",
    "summary": "Eli Lilly and Company (NYSE: LLY) today announced detailed results from ACHIEVE-3, the first head-to-head Phase 3 trial evaluating the safety and efficacy of orforglipron, a small molecule oral GLP-1 without food or water restrictions, compared with oral semaglutide in adults with type 2 diabetes inadequately controlled with metformin. The 52-week trial enrolled 1,698 participants across four treatment arms: orforglipron 12 mg and 36 mg, and oral semaglutide 7 mg and 14 mg. In ACHIEVE-3, orforgl",
    "url": "https://finnhub.io/api/news?id=aa8207c00f926f42893de93ac59df80335024a31e074c7ce0cfde92283ad3a48",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772105400,
      "headline": "Lilly's oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet",
      "id": 139230931,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) today announced detailed results from ACHIEVE-3, the first head-to-head Phase 3 trial evaluating the safety and efficacy of orforglipron, a small molecule oral GLP-1 without food or water restrictions, compared with oral semaglutide in adults with type 2 diabetes inadequately controlled with metformin. The 52-week trial enrolled 1,698 participants across four treatment arms: orforglipron 12 mg and 36 mg, and oral semaglutide 7 mg and 14 mg. In ACHIEVE-3, orforgl",
      "url": "https://finnhub.io/api/news?id=aa8207c00f926f42893de93ac59df80335024a31e074c7ce0cfde92283ad3a48"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Shared Detailed Results From ACHIEVE-3, the first head-to-head Phase 3 trial Of Orforglipron Compared With Oral Semaglutide, Outperforming Oral Semaglutide Across Primary And All Key Secondary Endpoints",
    "summary": "For the primary endpoint, orforglipron 36 mg lowered A1C by 2.2% vs. 1.4% with oral semaglutide 14 mg in ACHIEVE-3In a key secondary endpoint, participants on orforglipron 36 mg lost 19.7 lbs (9.2%) compared to 11.0 lbs",
    "url": "https://finnhub.io/api/news?id=9cb451aece005d3f57d161176b997e764168956865544e2e4d09764661eb5338",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772091380,
      "headline": "Eli Lilly Shared Detailed Results From ACHIEVE-3, the first head-to-head Phase 3 trial Of Orforglipron Compared With Oral Semaglutide, Outperforming Oral Semaglutide Across Primary And All Key Secondary Endpoints",
      "id": 139234445,
      "image": "",
      "related": "LLY",
      "source": "Benzinga",
      "summary": "For the primary endpoint, orforglipron 36 mg lowered A1C by 2.2% vs. 1.4% with oral semaglutide 14 mg in ACHIEVE-3In a key secondary endpoint, participants on orforglipron 36 mg lost 19.7 lbs (9.2%) compared to 11.0 lbs",
      "url": "https://finnhub.io/api/news?id=9cb451aece005d3f57d161176b997e764168956865544e2e4d09764661eb5338"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk's China Obesity Drug Cuts Nearly One-Fifth Of Body Weight",
    "summary": "The United Laboratories International Holdings Limited (TUL) and Novo Nordisk A/S (NYSE:NVO) on Tuesday shared topline results from a Chinese phase 2 trial of UBT251, a triple agonist of the receptors for GLP-1, GIP, and glucagon (triple G). In March 2025, the companies inked an exclusive license agreement worth over $2 billion in upfront and milestone payments. United Biotechnology is responsible for the development of UBT251 in the Chinese mainland, Hong Kong, Macau, and Taiwan, while Novo Nor",
    "url": "https://finnhub.io/api/news?id=8f9da4fb19907a478397c27efbc2040a07939e2f9c78a794b069927535174980",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772080273,
      "headline": "Novo Nordisk's China Obesity Drug Cuts Nearly One-Fifth Of Body Weight",
      "id": 139228641,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The United Laboratories International Holdings Limited (TUL) and Novo Nordisk A/S (NYSE:NVO) on Tuesday shared topline results from a Chinese phase 2 trial of UBT251, a triple agonist of the receptors for GLP-1, GIP, and glucagon (triple G). In March 2025, the companies inked an exclusive license agreement worth over $2 billion in upfront and milestone payments. United Biotechnology is responsible for the development of UBT251 in the Chinese mainland, Hong Kong, Macau, and Taiwan, while Novo Nor",
      "url": "https://finnhub.io/api/news?id=8f9da4fb19907a478397c27efbc2040a07939e2f9c78a794b069927535174980"
    }
  }
]